NL300537I2 - - Google Patents

Download PDF

Info

Publication number: NL300537I2
Authority: NL; Netherlands
Prior art keywords: sub; atoms; nitrogen; formula; fused
Prior art date: 2001-07-31

Application number

NL300537C

Other languages

English (en)

Original Assignee

Genzyme Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-07-31

Filing date

2012-06-28

Publication date

2017-02-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26976666&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL300537(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-06-28 Application filed by Genzyme Corp filed Critical Genzyme Corp

2017-02-02 Publication of NL300537I2 publication Critical patent/NL300537I2/nl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Developmental Biology & Embryology (AREA)
Cell Biology (AREA)
Biotechnology (AREA)
Diabetes (AREA)
Oncology (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Biochemistry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

NL300537C 2001-07-31 2012-06-28 NL300537I2 (nl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US30919601P	2001-07-31	2001-07-31
US38215502P	2002-05-20	2002-05-20
PCT/US2002/024212 WO2003011277A2 (en)	2001-07-31	2002-07-30	Methods to mobilize progenitor/stem cells

Publications (1)

Publication Number	Publication Date
NL300537I2 true NL300537I2 (nl)	2017-02-02

Family

ID=26976666

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NL300537C NL300537I2 (nl)	2001-07-31	2012-06-28
NL301031C NL301031I2 (nl)	2001-07-31	2020-01-22	Plerixafor, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of metaalcomplex daarvan

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NL301031C NL301031I2 (nl)	2001-07-31	2020-01-22	Plerixafor, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of metaalcomplex daarvan

Country Status (29)

Country	Link
US (9)	US6987102B2 (nl)
EP (3)	EP1411918B1 (nl)
JP (2)	JP5137288B2 (nl)
KR (2)	KR20040020075A (nl)
CN (2)	CN1561208B (nl)
AT (1)	ATE538785T1 (nl)
AU (1)	AU2002318927B2 (nl)
BE (1)	BE2019C544I2 (nl)
BR (1)	BRPI0211570B8 (nl)
CA (1)	CA2455559C (nl)
CY (4)	CY1112633T1 (nl)
DK (2)	DK1411918T3 (nl)
ES (2)	ES2742730T3 (nl)
FR (2)	FR12C0042I1 (nl)
HK (1)	HK1063005A1 (nl)
HU (1)	HUP0402360A2 (nl)
IL (2)	IL159312A0 (nl)
LT (2)	LT2371361T (nl)
LU (2)	LU92033I2 (nl)
MX (1)	MXPA04000982A (nl)
NL (2)	NL300537I2 (nl)
NO (4)	NO336989B1 (nl)
NZ (1)	NZ530169A (nl)
PL (1)	PL364673A1 (nl)
PT (2)	PT1411918E (nl)
RU (1)	RU2309741C2 (nl)
SI (2)	SI1411918T1 (nl)
WO (1)	WO2003011277A2 (nl)
ZA (1)	ZA200400658B (nl)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUP0402360A2 (hu) *	2001-07-31	2005-02-28	Anormed Inc.	Poliaminok alkalmazása progenitor sejtek és/vagy őssejtek számának növelésére alkalmas gyógyszerkészítmény előállítására
US7169750B2 (en) *	2001-07-31	2007-01-30	Anormed, Inc.	Methods to mobilize progenitor/stem cells
EP1465889B1 (en)	2001-12-21	2017-03-22	Genzyme Corporation	Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US7354932B2 (en) *	2001-12-21	2008-04-08	Anormed, Inc.	Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US20050153941A1 (en) *	2003-06-27	2005-07-14	Tomoyuki Miyabayashi	Cell differntiation inhibiting agent, cell culture method using the same, culture medium, and cultured cell line
WO2005002522A2 (en) *	2003-06-30	2005-01-13	Caritas St. Elizabeth's Medical Center Of Boston, Inc.	Compositions and methods for treating tissue ischemia
WO2005017161A2 (en)	2003-08-13	2005-02-24	Children's Hospital Medical Center	Chimeric peptides for the regulation of gtpases
US7417026B2 (en)	2003-08-13	2008-08-26	Children's Hospital Medical Center	Mobilization of hematopoietic cells
IL158868A0 (en) *	2003-11-13	2004-05-12	Yeda Res & Dev	Methods of generating and using stem cells enriched with immature primitive progenitor
WO2005103721A1 (en) *	2004-04-20	2005-11-03	Bayer Healthcare Ag	Diagnostics and therapeutics for diseases associated with cxc chemokine receptor 4 (cxcr4)
AU2005272653A1 (en) *	2004-08-13	2006-02-23	Anormed Inc.	Chemokine combinations to mobilize progenitor/stem cells
US7785582B2 (en) *	2004-09-07	2010-08-31	Johnson Lanny L	Use of synovium and omentum for tissue engineering
US8182806B2 (en) *	2004-09-07	2012-05-22	Johnson Lanny L	Synovial villi for use with tissue engineering
EP1814587A2 (en) *	2004-11-05	2007-08-08	The General Hospital Corporation	Purposeful movement of human migratory cells away from an agent source
CA2612102C (en)	2005-06-13	2016-02-09	Cleveland Biolabs, Inc.	Methods of protecting against apoptosis using lipopeptides
JP2009504788A (ja) *	2005-08-19	2009-02-05	ジェンザイム・コーポレーション	化学療法の強化方法
EP2267030A1 (en) *	2005-08-25	2010-12-29	Repair Technologies, Inc.	Devices, compositions and methods for the protection and repair of cells and tissues
US7927630B2 (en) *	2005-09-12	2011-04-19	Johnson Lanny L	Use of autologous sediment from fluid aspirates as vehicles for drug delivery
US8518349B2 (en)	2005-09-12	2013-08-27	Lanny Johnson	Use of autologous sediment from fluid aspirates as vehicles for drug delivery
US20070116680A1 (en) *	2005-11-18	2007-05-24	Rensselaer Polytechnic Institute	Stem cells within gel microenvironments
CA2643209A1 (en) *	2006-02-24	2007-09-20	Genzyme Corporation	Methods for increasing blood flow and/or promoting tissue regeneration
WO2007108689A2 (en) *	2006-03-21	2007-09-27	Stichting Skeletal Tissue Engineering	Method for induction of differentiation of stem and progenitor cells
RU2009108289A (ru) *	2006-08-07	2010-09-20	Джензим Корпорейшн (Us)	Комбинированная терапия
US7883698B2 (en) *	2007-01-17	2011-02-08	Maria Michejda	Isolation and preservation of fetal hematopoietic and mesencymal system cells from non-controversial materials and/or tissues resulting from miscarriages and methods of therapeutic use
WO2010025416A1 (en) *	2008-08-29	2010-03-04	Genzyme Corporation	Cxcr4 antagonists for kidney injury
EP2493295A4 (en) *	2009-10-28	2013-05-08	Ford Henry Health System	METHOD FOR MINIMIZING LESIONS DUE TO RADIATION EXPOSURE
CN101716167B (zh) *	2009-12-08	2011-12-28	中国人民解放军军事医学科学院野战输血研究所	一类饱和胺类化合物在制备外周血造血干细胞动员药物中的应用
EP2600901B1 (en)	2010-08-06	2019-03-27	ModernaTX, Inc.	A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
KR20140045411A (ko)	2011-05-16	2014-04-16	젠자임 코포레이션	Ｃｘｃｒ４ 길항제의 용도
EP2968563A4 (en) *	2013-03-15	2016-11-30	Leonard B Miller	COMBINED TREATMENT TO IMPROVE MOU TISSUE HEALING, HEALING ADIPOSE TISSUE GRAFT, ENDOCHREST BONE SEWAGE AND OSTEOINTEGRATION
US9988973B2 (en)	2015-01-06	2018-06-05	Hamilton Sundstrand Corporation	Water injector for aviation cooling system
AU2016324160A1 (en)	2015-09-18	2018-04-26	The General Hospital Corporation Dba Massachusetts General Hospital	Localized delivery of anti-fugetactic agent for treatment of cancer
CA3008272A1 (en)	2015-12-14	2017-06-22	X4 Pharmaceuticals, Inc.	Methods for treating cancer
WO2017106332A1 (en)	2015-12-14	2017-06-22	X4 Pharmaceuticals, Inc.	Methods for treating cancer
US11433136B2 (en)	2015-12-18	2022-09-06	The General Hospital Corporation	Polyacetal polymers, conjugates, particles and uses thereof
PL3393468T3 (pl)	2015-12-22	2023-01-23	X4 Pharmaceuticals, Inc.	Metody leczenia niedoboru odporności
CA3019394A1 (en)	2016-04-08	2017-10-12	X4 Pharmaceuticals, Inc.	Methods for treating cancer
US11433048B2 (en) *	2016-06-16	2022-09-06	Centre National De La Recherche Scientifique	CXCR4 receptor-binding compounds useful for increasing interferon level
US10759796B2 (en)	2016-06-21	2020-09-01	X4 Pharmaceuticals, Inc.	CXCR4 inhibitors and uses thereof
EP3471726A4 (en)	2016-06-21	2019-10-09	X4 Pharmaceuticals, Inc.	CXCR4 INHIBITORS AND USES THEREOF
US11332470B2 (en)	2016-06-21	2022-05-17	X4 Pharmaceuticals, Inc.	CXCR4 inhibitors and uses thereof
WO2018049118A1 (en)	2016-09-09	2018-03-15	The General Hospital Corporation	Hsp fusion protein with anti-chemorepellant agent for treatment of cancer
US11364264B2 (en)	2016-09-09	2022-06-21	The General Hospital Corporation	Ex vivo antigen-presenting cells or activated CD-positive T cells for treatment of cancer
WO2018049124A1 (en)	2016-09-09	2018-03-15	The General Hospital Corporation	Hsp fusion protein with anti-chemorepellant agent for treatment of infectious disease
WO2018106738A1 (en)	2016-12-05	2018-06-14	Massachusetts Institute Of Technology	Brush-arm star polymers, conjugates and particles, and uses thereof
WO2019113375A2 (en) *	2017-12-06	2019-06-13	Magenta Therapeutics, Inc.	Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
US10058573B1 (en)	2017-12-06	2018-08-28	Magenta Therapeutics, Inc.	Dosing regimens for the mobilization of hematopoietic stem cells
US11260079B2 (en)	2017-12-06	2022-03-01	Magenta Therapeutics, Inc.	Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
JP7517986B2 (ja) *	2017-12-19	2024-07-17	ジーピーシーアールセラピューティクス，インク．	Ｇｐｃｒヘテロマー阻害剤及びその用途
US10548889B1 (en)	2018-08-31	2020-02-04	X4 Pharmaceuticals, Inc.	Compositions of CXCR4 inhibitors and methods of preparation and use
US12059437B2 (en)	2019-10-08	2024-08-13	The Regents Of The University Of California	Methods and compositions for hematopoietic stem cell mobilization
EP4146797A1 (en)	2020-05-06	2023-03-15	Orchard Therapeutics (Europe) Limited	Treatment for neurodegenerative diseases
CA3234340A1 (en)	2021-10-01	2023-04-06	Janssen Pharmaceutica N.V.	Methods of increasing progenitor cell production

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US562476A (en) *		1896-06-23		Combined fence-wire reel and straightener
US4111199A (en) *	1977-03-31	1978-09-05	Isaac Djerassi	Method of collecting transfusable granulocytes by gravity leukopheresis
US4810643A (en)	1985-08-23	1989-03-07	Kirin- Amgen Inc.	Production of pluripotent granulocyte colony-stimulating factor
US4994560A (en)	1987-06-24	1991-02-19	The Dow Chemical Company	Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
DE3728525A1 (de)	1987-08-24	1989-03-16	Schering Ag	Mehrkernige substituierte komplexbildner, komplexe und komplexsalze, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel
FR2644453A1 (fr) *	1989-03-20	1990-09-21	Centre Nat Rech Scient	Procede de preparation de tetramines cycliques monofonctionnalisees
WO1991005762A1 (en)	1989-10-23	1991-05-02	Cockbain, Julian, Roderick, Michaelson	Multi-site metal chelating agents
US5021409A (en)	1989-12-21	1991-06-04	Johnson Matthey Plc	Antiviral cyclic polyamines
US6001826A (en)	1989-12-21	1999-12-14	Anormed, Inc.	Chemical compounds
FR2672051B1 (fr) *	1991-01-24	1993-05-21	Guerbet Sa	Nouveaux ligands macrocycliques azotes, procede de preparation, complexes polymetalliques, composition de diagnostic et therapeutique.
GB9105489D0 (en)	1991-03-15	1991-05-01	Johnson Matthey Plc	Improvements in chemical compounds
GB9126677D0 (en)	1991-12-16	1992-02-12	Johnson Matthey Plc	Improvements in chemical compounds
EP0670735B1 (en)	1992-11-13	1997-04-02	Board Of Regents Of The University Of Washington	Peripheralization of hematopoietic stem cells
GB9400411D0 (en)	1994-01-11	1994-03-09	Johnson Matthey Plc	Improvements in chemical compounds
JPH08127539A (ja) *	1994-10-31	1996-05-21	Ajinomoto Co Inc	ヒトｉｌ−１１を含有する末梢血幹細胞増加剤
US5612478A (en)	1995-03-30	1997-03-18	Johnson Matthey Plc	Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
US5606053A (en)	1995-05-02	1997-02-25	Johnson Matthey Plc	Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
JPH0952824A (ja) *	1995-06-05	1997-02-25	Nippon Kayaku Co Ltd	末梢血液中の造血幹細胞数を増加するための薬剤
GB9511357D0 (en)	1995-06-06	1995-08-02	Johnson Matthey Plc	Improved antiviral compounds
US6506770B1 (en)	1996-06-06	2003-01-14	Anormed, Inc.	Antiviral compounds
US5811544A (en) *	1995-08-28	1998-09-22	Johnson Matthey Plc	Process for preparing 1,4,8,11-tetraazacyclotetradecane
CA2305787A1 (en) *	2000-05-09	2001-11-09	The University Of British Columbia	Cxcr4 antagonist treatment of hematopoietic cells
AU766675B2 (en) *	1998-03-30	2003-10-23	Northwest Biotherapeutics, Inc.	Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis
AU4696899A (en) *	1998-06-19	2000-01-05	General Hospital Corporation, The	Modulating platelet function
CA2244554A1 (en) *	1998-07-30	2000-01-30	Vasogen Inc.	Inhibition of graft versus host disease
JP2003523166A (ja) *	1998-09-29	2003-08-05	ガミダセルリミテッド	幹細胞および前駆細胞の増殖と分化を制御する方法
JP2002529502A (ja) *	1998-11-17	2002-09-10	スミスクライン・ビーチャム・コーポレイション	血小板減少症の治療法
EP1016413A1 (en) *	1998-12-30	2000-07-05	Applied Research Systems ARS Holding N.V.	Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells
US6365583B1 (en) *	1999-02-02	2002-04-02	Anormed, Inc.	Methods to enhance white blood cell count
CN1219780C (zh)	1999-03-24	2005-09-21	阿诺麦德股份有限公司	结合趋化因子受体的杂环化合物
EP1189609A4 (en) *	1999-05-03	2002-10-30	Smithkline Beecham Corp	CXCR-4 RECEPTOR ANTAGONISTS AND THROMBOPOIETIN MIMETIKA
CA2389545C (en) *	1999-12-17	2010-08-31	Anormed Inc.	Chemokine receptor binding heterocyclic compounds
JP2003532683A (ja)	2000-05-09	2003-11-05	ザユニバーシティオブブリティッシュコロンビア	造血細胞のｃｘｃｒ４アンタゴニスト治療
CA2412436C (en) *	2000-06-05	2013-05-21	The Trustees Of Columbia University In The City Of New York	Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury
NZ524420A (en)	2000-09-15	2005-04-29	Anormed Inc	Chemokine receptor binding heterocyclic compounds
HUP0302960A3 (en)	2000-09-15	2007-03-28	Anormed Inc	Chemokine receptor binding heterocyclic compounds, their use and pharmaceutical compositions contining them
CN1237061C (zh)	2000-09-15	2006-01-18	阿诺麦德股份有限公司	结合趋化因子受体的杂环化合物
PL359292A1 (en)	2000-09-29	2004-08-23	Anormed Inc.	Process for preparation of n-1 protected n ring nitrogen containing cyclic polyamines and products thereof
MXPA03006542A (es)	2001-01-23	2003-09-22	P & G Clairol Inc	Intermediarios primarios para la coloracion oxidativa del cabello.
US7169750B2 (en) *	2001-07-31	2007-01-30	Anormed, Inc.	Methods to mobilize progenitor/stem cells
HUP0402360A2 (hu)	2001-07-31	2005-02-28	Anormed Inc.	Poliaminok alkalmazása progenitor sejtek és/vagy őssejtek számának növelésére alkalmas gyógyszerkészítmény előállítására
EP1465889B1 (en)	2001-12-21	2017-03-22	Genzyme Corporation	Chemokine receptor binding heterocyclic compounds with enhanced efficacy
DE102014206089B4 (de)	2014-03-31	2018-01-18	BSH Hausgeräte GmbH	Haushaltskältegerät mit einer Spendereinheit mit zwei Verschlusselementen an einem Ausführkanal

2002
- 2002-07-30 HU HU0402360A patent/HUP0402360A2/hu unknown
- 2002-07-30 WO PCT/US2002/024212 patent/WO2003011277A2/en active Search and Examination
- 2002-07-30 KR KR10-2004-7001333A patent/KR20040020075A/ko not_active Application Discontinuation
- 2002-07-30 LT LTEP10184509.7T patent/LT2371361T/lt unknown
- 2002-07-30 NZ NZ530169A patent/NZ530169A/en not_active IP Right Cessation
- 2002-07-30 EP EP02750370A patent/EP1411918B1/en not_active Revoked
- 2002-07-30 PT PT02750370T patent/PT1411918E/pt unknown
- 2002-07-30 EP EP19179517.8A patent/EP3632425A1/en not_active Withdrawn
- 2002-07-30 PL PL02364673A patent/PL364673A1/xx unknown
- 2002-07-30 AU AU2002318927A patent/AU2002318927B2/en not_active Expired
- 2002-07-30 DK DK02750370.5T patent/DK1411918T3/da active
- 2002-07-30 DK DK10184509.7T patent/DK2371361T3/da active
- 2002-07-30 KR KR1020097024731A patent/KR100996378B1/ko active IP Right Grant
- 2002-07-30 CN CN028149955A patent/CN1561208B/zh not_active Expired - Lifetime
- 2002-07-30 CA CA2455559A patent/CA2455559C/en not_active Expired - Lifetime
- 2002-07-30 PT PT10184509T patent/PT2371361T/pt unknown
- 2002-07-30 MX MXPA04000982A patent/MXPA04000982A/es active IP Right Grant
- 2002-07-30 IL IL15931202A patent/IL159312A0/xx unknown
- 2002-07-30 EP EP10184509.7A patent/EP2371361B1/en not_active Revoked
- 2002-07-30 JP JP2003516507A patent/JP5137288B2/ja not_active Expired - Lifetime
- 2002-07-30 ES ES10184509T patent/ES2742730T3/es not_active Expired - Lifetime
- 2002-07-30 SI SI200230976T patent/SI1411918T1/sl unknown
- 2002-07-30 BR BR0211570-0 patent/BRPI0211570B8/pt not_active IP Right Cessation
- 2002-07-30 AT AT02750370T patent/ATE538785T1/de active
- 2002-07-30 US US10/209,001 patent/US6987102B2/en not_active Expired - Lifetime
- 2002-07-30 CN CN201010282230.3A patent/CN102302493B/zh not_active Expired - Lifetime
- 2002-07-30 ES ES02750370T patent/ES2380009T3/es not_active Expired - Lifetime
- 2002-07-30 SI SI200231096T patent/SI2371361T1/sl unknown
- 2002-07-30 RU RU2004105961/15A patent/RU2309741C2/ru active Protection Beyond IP Right Term
2003
- 2003-12-11 IL IL159312A patent/IL159312A/en active IP Right Grant
2004
- 2004-01-27 ZA ZA2004/00658A patent/ZA200400658B/en unknown
- 2004-01-29 NO NO20040407A patent/NO336989B1/no active Protection Beyond IP Right Term
- 2004-06-18 HK HK04104446.8A patent/HK1063005A1/xx not_active IP Right Cessation
2005
- 2005-11-08 US US11/269,773 patent/US7935692B2/en not_active Expired - Lifetime
2006
- 2006-06-02 US US11/446,390 patent/US20060223180A1/en not_active Abandoned
2007
- 2007-08-20 US US11/841,837 patent/US7897590B2/en not_active Expired - Lifetime
2008
- 2008-04-11 JP JP2008104148A patent/JP2008195730A/ja not_active Withdrawn
2011
- 2011-02-08 US US13/023,381 patent/US20110129448A1/en not_active Abandoned
2012
- 2012-03-07 CY CY20121100223T patent/CY1112633T1/el unknown
- 2012-06-27 LU LU92033C patent/LU92033I2/fr unknown
- 2012-06-27 CY CY2012017C patent/CY2012017I1/el unknown
- 2012-06-28 FR FR12C0042C patent/FR12C0042I1/fr active Active
- 2012-06-28 NL NL300537C patent/NL300537I2/nl unknown
2013
- 2013-03-14 US US13/826,913 patent/US20130273009A1/en not_active Abandoned
2014
- 2014-10-03 US US14/506,297 patent/US20150246019A1/en not_active Abandoned
2015
- 2015-05-27 NO NO20150674A patent/NO344632B1/no not_active IP Right Cessation
2016
- 2016-03-18 US US15/074,836 patent/US20170049747A1/en not_active Abandoned
- 2016-06-10 NO NO2016011C patent/NO2016011I1/no unknown
2018
- 2018-08-21 US US16/107,761 patent/US20190216773A1/en not_active Abandoned
2019
- 2019-08-20 CY CY20191100889T patent/CY1122199T1/el unknown
- 2019-10-10 FR FR19C1058C patent/FR19C1058I2/fr active Active
- 2019-10-14 CY CY2019038C patent/CY2019038I2/el unknown
- 2019-10-23 BE BE2019C544C patent/BE2019C544I2/fr unknown
- 2019-11-19 LT LTPA2019018C patent/LTC2371361I2/lt unknown
- 2019-11-26 LU LU00139C patent/LUC00139I2/fr unknown
2020
- 2020-01-22 NL NL301031C patent/NL301031I2/nl unknown
- 2020-03-05 NO NO2020003C patent/NO2020003I1/no unknown

Also Published As

Publication number	Publication date
LUC00139I1 (nl)	2019-11-27
FR19C1058I2 (fr)	2020-10-23
RU2309741C2 (ru)	2007-11-10
US20170049747A1 (en)	2017-02-23
EP1411918A4 (en)	2007-11-14
EP2371361A1 (en)	2011-10-05
CN102302493B (zh)	2015-08-12
NL301031I2 (nl)	2020-07-20
EP1411918A2 (en)	2004-04-28
NO336989B1 (no)	2015-12-14
SI2371361T1 (sl)	2019-10-30
WO2003011277A3 (en)	2003-05-22
EP3632425A1 (en)	2020-04-08
NO20150674A1 (no)	2015-05-27
CY2012017I2 (el)	2015-08-05
FR19C1058I1 (nl)	2019-11-22
NO344632B1 (no)	2020-02-17
US7935692B2 (en)	2011-05-03
US20080063624A1 (en)	2008-03-13
NZ530169A (en)	2007-04-27
LT2371361T (lt)	2019-09-10
CA2455559C (en)	2012-01-10
KR100996378B1 (ko)	2010-11-25
BRPI0211570B8 (pt)	2021-05-25
US20060223180A1 (en)	2006-10-05
LU92033I2 (fr)	2012-08-27
CA2455559A1 (en)	2003-02-13
JP2004538303A (ja)	2004-12-24
US20060193826A1 (en)	2006-08-31
BRPI0211570B1 (pt)	2020-01-28
US7897590B2 (en)	2011-03-01
CN1561208A (zh)	2005-01-05
PT1411918E (pt)	2012-03-06
JP5137288B2 (ja)	2013-02-06
US20030130250A1 (en)	2003-07-10
ZA200400658B (en)	2005-07-27
ATE538785T1 (de)	2012-01-15
LTC2371361I2 (lt)	2021-09-27
CY2012017I1 (el)	2015-08-05
EP1411918B1 (en)	2011-12-28
LU92033I9 (nl)	2019-01-03
KR20040020075A (ko)	2004-03-06
ES2742730T3 (es)	2020-02-17
US20150246019A1 (en)	2015-09-03
IL159312A (en)	2015-05-31
ES2380009T3 (es)	2012-05-07
CY1112633T1 (el)	2015-08-05
HK1063005A1 (en)	2004-12-10
SI1411918T1 (sl)	2012-04-30
BR0211570A (pt)	2004-07-13
FR12C0042I1 (fr)	2012-08-10
US20110129448A1 (en)	2011-06-02
US20190216773A1 (en)	2019-07-18
CY2019038I1 (el)	2020-05-29
CN1561208B (zh)	2010-11-10
PL364673A1 (en)	2004-12-13
AU2002318927B2 (en)	2007-01-04
NO2016011I1 (no)	2016-06-10
EP2371361B1 (en)	2019-08-07
CY2019038I2 (el)	2020-05-29
CY1122199T1 (el)	2020-05-29
US20130273009A1 (en)	2013-10-17
NO20040407L (no)	2004-03-19
IL159312A0 (en)	2004-06-01
BE2019C544I2 (nl)	2021-07-19
NO2020003I1 (no)	2020-03-05
LUC00139I2 (nl)	2021-02-10
JP2008195730A (ja)	2008-08-28
PT2371361T (pt)	2019-09-10
RU2004105961A (ru)	2005-03-20
NL301031I1 (nl)	2020-02-05
MXPA04000982A (es)	2004-04-20
CN102302493A (zh)	2012-01-04
HUP0402360A2 (hu)	2005-02-28
DK1411918T3 (da)	2012-04-23
US6987102B2 (en)	2006-01-17
DK2371361T3 (da)	2019-08-19
WO2003011277A2 (en)	2003-02-13
KR20090130152A (ko)	2009-12-17
LTPA2019018I1 (lt)	2019-12-10

Publication	Publication Date	Title
LUC00139I1 (nl)	2019-11-27
AP1497A (en)	2005-11-20	Methods and compositions to enhance white blood cell count.
HUP0004259A2 (hu)	2001-04-28	VLA-4 által mediált leukocita adhéziót gátló szubsztituált fenilalanin-származékok, ezeket tartalmazó gyógyászati készítmények
KR930006027A (ko)	1993-04-20	엔케팔리나제 및 안지오텐신 전환 효소(ace)의 억제제로서 유용한 2-치환 인단-2-메르캅토아세틸아미드 유도체
MXPA05003193A (es)	2005-06-08	Compuesto de adenina novedoso y uso del mismo.
KR920012082A (ko)	1992-07-25	Ace 억제제로서 유용한 신규 아미노 및 니트로 함유 삼환식 화합물
ES2164164T3 (es)	2002-02-16	Derivados de aminotetrazol utiles como inhibidores de oxido nitrico sintasa.
EA200501148A1 (ru)	2006-04-28	Пиридилоксиметильные и бензизоксазольные азабициклические производные
ATE258050T1 (de)	2004-02-15	Verwendung neurogen-entzuendungshemmender verbindungen und zusammensetzungen
ATE46511T1 (de)	1989-10-15	Neue 8-alkylthio-2-piperazino-pyrimido(5,4d>pyrimidine, ihre herstellung und diese verbindungen enthaltende arzneimittel.
EP1142883A4 (en)	2002-08-21	HETEROCYCLIC COMPOUNDS AND MEDICINAL COMPOSITIONS THAT CONTAIN THEM
OA09239A (fr)	1992-06-30	"Nouveaux céphèmes et procédés pour leur préparation".
WO2007106063A3 (en)	2007-12-21	Methods for increasing blood flow and/or promoting tissue regeneration
EP1057829A4 (en)	1999-12-10	Condensed pyrimidine derivatives and pharmaceutical compositions containing them
ES8605524A1 (es)	1986-03-16	Procedimiento para preparar tieno- y furo-(2,3-c)-pirroles
EA200001157A2 (ru)	2001-06-25	Новые замещенные производные (дигидро)бензоксазина и (дигидро)бензотиазина, способ их получения и содержащие их фармацевтические композиции